Jul 30, 2018
According to the World Health Organization, type 2 diabetes
comprises the majority of the more than 400 million people with
diabetes around the world. In efforts to better understand the
disease, metabolomics measurements have identified tryptophan
metabolites as potential biological mediators in the development of
type 2 diabetes.
The PREDIMED trial was a multi-center trial of Mediterranean-style
diets where the primary prevention of cardiovascular events that
also included type 2 diabetes as a secondary end point. An original
research article published in the August 2018 issue of Clinical
Chemistry studies whether tryptophan metabolites in PREDIMED
participants were associated with development of type 2 diabetes
and insulin resistance.